Literature DB >> 31535299

The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes).

Danielle M Bello1, Mark B Faries2.   

Abstract

Management of regional lymph nodes in patients with melanoma has evolved significantly in recent years. The value of nodal intervention, long utilized for its perceived therapeutic benefit, has now shifted to that of a critical prognostic procedure used to guide clinical decision making. This review focuses on the three landmark, randomized controlled trials evaluating the role of surgery for regional lymph nodes in melanoma: Multicenter Selective Lymphadenectomy Trial I (MSLT-I), German Dermatologic Cooperative Oncology Group-Selective Lymphadenectomy Trial (DeCOG-SLT), and Multicenter Selective Lymphadenectomy Trial II (MSLT-II).

Entities:  

Mesh：

Year:  2019        PMID： 31535299     DOI： 10.1245/s10434-019-07830-w

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


  10 in total

1.  Completely resected stage III melanoma controversy - 15 years of national tertiary centre experience.

Authors:  Barbara Peric; Sara Milicevic; Andraz Perhavec; Marko Hocevar; Janez Zgajnar
Journal:  Radiol Oncol       Date:  2020-10-08       Impact factor: 2.991

2.  National Practice Patterns in the Management of the Regional Lymph Node Basin After Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma.

Authors:  Cimarron E Sharon; Richard J Straker; Eric H Li; Giorgos C Karakousis; John T Miura
Journal:  Ann Surg Oncol       Date:  2022-08-25       Impact factor: 4.339

3.  Completely resected stage III melanoma controversy - 15 years of national tertiary centre experience.

Authors:  Barbara Peric; Sara Milicevic; Andraz Perhavec; Marko Hocevar; Janez Zgajnar
Journal:  Radiol Oncol       Date:  2020-10-08       Impact factor: 2.991

4.  Role of sentinel lymph node biopsy for cutaneous melanoma in elderly patients: preliminary results in a Latin-American population.

Authors:  Carola Featherston; Walter Sebastián Nardi; Florencia Rocio Tomé; Sergio Damian Quildrian
Journal:  Ecancermedicalscience       Date:  2021-01-13

5.  Recent Evolution in the Management of Lymph Node Metastases in Melanoma.

Authors:  Shelby Breit; Elise Foley; Elizabeth Ablah; Hayrettin Okut; Joshua Mammen
Journal:  Kans J Med       Date:  2021-03-19

6.  Prognostic factors and population-based analysis of melanoma with sentinel lymph node biopsy.

Authors:  Ping-Chung Wu; Yu-Ching Chen; Hsiu-Min Chen; Lee-Wei Chen
Journal:  Sci Rep       Date:  2021-10-15       Impact factor: 4.379

Review 7.  Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials.

Authors:  Simone Amabile; Gabriele Roccuzzo; Valentina Pala; Luca Tonella; Marco Rubatto; Martina Merli; Paolo Fava; Simone Ribero; Maria Teresa Fierro; Paola Queirolo; Pietro Quaglino
Journal:  J Clin Med       Date:  2021-11-23       Impact factor: 4.241

Review 8.  Predictive factors of neoadjuvant immune checkpoint blockade in melanoma.

Authors:  Melissa Sarver; Michael C Brown; Kristen E Rhodin; April K S Salama; Georgia M Beasley
Journal:  Hum Vaccin Immunother       Date:  2021-07-13       Impact factor: 4.526

9.  Metastatic Merkel cell carcinoma and malignant melanoma in a single sentinel lymph node.

Authors:  Amanda Hamilton; Prasad Jayaratne; Mark Zonta
Journal:  SAGE Open Med Case Rep       Date:  2021-06-16

10.  The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma.

Authors:  Lutz Kretschmer; Christina Mitteldorf; Simin Hellriegel; Andreas Leha; Alexander Fichtner; Philipp Ströbel; Michael P Schön; Felix Bremmer
Journal:  Mod Pathol       Date:  2021-06-15       Impact factor: 7.842
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.